Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.
Press releases published on April 30, 2025
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
GlobeNewswire
·
April 30, 2025
Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications and collaborations Plans to partially spin off RNA …
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
GlobeNewswire
·
April 30, 2025
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at the American Academy of Neurology …
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewswire
·
April 30, 2025
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ …
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire
·
April 30, 2025
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that …
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
April 30, 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for …
Altimmune to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life …
InflaRx to Report First Quarter 2025 Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …
BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire
·
April 30, 2025
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, …
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
April 30, 2025
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim …
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
GlobeNewswire
·
April 30, 2025
Sanofi and CD…
Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public
GlobeNewswire
·
April 30, 2025
Sanofi et CD…
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today …
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer …
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025
GlobeNewswire
·
April 30, 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …
10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure
GlobeNewswire
·
April 30, 2025
BEND, Ore., April 30, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY) craft beer brand, is excited to announce the launch of NA Apocalypse IPA, a non-alcoholic version of their beloved Apocalypse IPA. This …
Nusano Names Rachel Culbertson VP of Supply Chain
GlobeNewswire
·
April 30, 2025
WEST VALLEY CITY, Utah, April 30, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the appointment of Rachel Culbertson as Vice President of Supply Chain. Culbertson’s leadership will be …
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing …
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
GlobeNewswire
·
April 30, 2025
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …
Larimar Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end …
I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025
GlobeNewswire
·
April 30, 2025
ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for …